Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients

To the Editor: Dupilumab is a fully human monoclonal antibody that binds the interleukin (IL) 4 receptor-α subunit and inhibits signaling of IL-4 and IL-13. It was approved by the Food and Drug Administration for the treatment of moderate to severe atopic dermatitis in adults and adolescents, with efficacy in reducing pruritus.1Gooderham M.J. Hong H.C.-H. Eshtiaghi P. Papp K.A. Dupilumab: a review of its use in the treatment of atopic...